Status:
COMPLETED
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Non-alcoholic Steatohepatitis
Eligibility:
MALE
20-55 years
Phase:
PHASE1
Brief Summary
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment partici...
Eligibility Criteria
Inclusion
- Male, aged 20-55 years (both inclusive) at the time of signing informed consent
- For Japanese subjects only, both parents of Japanese descent. For non-Asian subjects only, both parents of non-Asian descent
- Body mass index (BMI) between 23.0 and 34.9 kg/m\^2 (both inclusive)
- Body weight greater than or equal to 60 kg
Exclusion
- Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
- Subjects aged above or equal to 40 years with an estimated 10-year atherosclerotic cardiovascular disease risk (as described in the American College of Cardiology and the American Heart Association Prevention Guideline) greater than or equal to 5 percentage
Key Trial Info
Start Date :
February 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2021
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT04722653
Start Date
February 2 2021
End Date
April 27 2021
Last Update
April 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 130-0004